The market is witnessing significant advancement, driven by innovative research and development in biotechnology. These cells are extensively utilized in the production of therapeutic proteins, vaccines, and monoclonal antibodies, fueling the biopharmaceutical industry's growth. Their ability to efficiently express complex proteins and glycosylation patterns offers substantial benefits, including enhanced product yields and improved bioactivity. Moreover, advancements in cell line engineering techniques and bioprocessing technologies continue to optimize CHO cell-based production, promising further market expansion and diversification of applications.
Data Bridge Market Research analyses that the Global Chinese Hamster Ovary (CHO) Cells Market size is expected to reach USD 659,479.05 thousand by 2030 from USD 354,047.75 thousand in 2022, with the CAGR of 8.5% in the forecast period of 2023 to 2030.
Below are the Top Five Chinese Hamster Ovary (CHO) CELLS Companies with a Significant Market Share:
|
Rank
|
Company
|
Overview
|
Product/Service Portfolio
|
Sales Geographical Coverage
|
Developments
|
|
1.
|
Lonza
|
Lonza is a leading supplier of products and services for the biopharmaceutical industry, including cell culture media and bioprocessing equipment. In the Chinese Hamster Ovary (CHO) cells market, Lonza offers a range of CHO cell lines, media, and services for cell line development and bioproduction. Their expertise in cell culture and bioprocessing enables pharmaceutical companies to efficiently produce therapeutic proteins using CHO cells, meeting the growing demand for biologics in the Chinese market.
|
|
America, Europe, Asia-Pacific, Middle East and Africa
|
In July 2023, Lonza launched TheraPRO CHO Media System, a new cell culture medium that simplifies processes and optimizes productivity and protein quality when using GS-CHO cell lines. The start-up supports pharmaceutical and biotech companies producing therapeutic proteins to improve product quality further. The TheraPRO CHO Media System provides efficient performance, achieving high concentrations of viable cells and protein titers above 5 g/L over a 15-day culture period. This represents more than double the protein titer that can be produced with commercially available solutions. This launch has helped the company to expand its product portfolio in the market.
|
|
2.
|
Sartorius AG
|
Sartorius AG provides a comprehensive portfolio of products and services for biopharmaceutical manufacturing, including cell culture technologies tailored for CHO cells. In the Chinese Hamster Ovary (CHO) cells market, Sartorius offers innovative bioprocessing solutions, such as bioreactors, filtration systems, and analytical instruments, to support efficient and scalable production of biologics. Their expertise in process development and optimization empowers biopharmaceutical companies in China to streamline their production workflows and accelerate time to market for novel therapeutics.
|
|
America, Europe, Asia-Pacific, Middle East and Africa
|
In February 2022, Sartorius acquired business from Novasep and added a complementary offering to its chromatography portfolio. The acquired portfolio includes chromatography systems primarily suited for small biomolecules such as oligonucleotides, peptides, and insulin, and innovative systems for the continuous production of biopharmaceuticals.
|
|
3.
|
Merck KGaA
|
Merck KGaA is a global leader in providing products and services for the life science industry, including solutions for Chinese Hamster Ovary (CHO) cell culture. In the CHO cells market, Merck offers a diverse range of cell culture media, supplements, and cell line engineering technologies to optimize protein expression and production. With their extensive expertise in bioprocessing and biomanufacturing, Merck enables biopharmaceutical companies in China to achieve high yields and product quality while ensuring regulatory compliance and operational efficiency.
|
|
Middle East and Africa, Europe, America, and Asia-Pacific
|
In July 2023, Merck announced that it is expanding its facility in Lenexa, Kansas, U.S., adding 9,100 square meters of laboratory space and production capacity for the production of cell culture media. This expansion makes Lenexa the company's largest dry powder cell culture facility and a center of excellence in North America. The investment in the region reflects the company's strategy to expand and diversify its supply chain to meet current and future demand for cell culture platforms.
|
|
4.
|
Cytiva
|
Cytiva, formerly part of GE Healthcare Life Sciences, specializes in providing technologies and services for bioprocessing applications, including Chinese Hamster Ovary (CHO) cell culture. In the CHO cells market, Cytiva offers a wide range of products, including cell culture media, chromatography resins, and filtration systems, designed to enhance productivity and yield in biopharmaceutical production. Their advanced bioprocessing solutions enable biopharmaceutical companies in China to overcome challenges and accelerate the development and manufacturing of innovative biologics for various therapeutic applications.
|
|
North America, Europe, and Asia-Pacific
|
Experience unparalleled productivity and regulatory compliance with HyCell CHO media from Cytiva. Engineered specifically for Chinese hamster ovary (CHO) cell culture, these chemically defined and animal-derived component-free solutions ensure high yields and quality in recombinant protein production. Ideal for large-scale applications, including perfusion and fed-batch strategies, HyCell CHO supports seamless adaptation and exceptional performance from shake flasks to bioreactors.
|
|
5.
|
Thermo Fisher Scientific Inc.
|
Thermo Fisher Scientific Inc. is a leading provider of products and services for the life sciences industry, offering solutions for Chinese Hamster Ovary (CHO) cell culture and bioprocessing. In the CHO cells market, Thermo Fisher Scientific provides a comprehensive portfolio of cell culture media, supplements, and bioproduction equipment to support efficient protein expression and purification. Their integrated solutions enable biopharmaceutical companies in China to streamline their workflows, reduce time to market, and meet the increasing demand for biologics with high quality and consistency.
|
|
Middle East and Africa, Europe, Asia-Pacific, America
|
In October 2022, Thermo Fisher Scientific Inc. collaborated with ProBioGen to develop better platform, the Gibco Freedom ExpiCHO-S Cell Line Development Kit. This kit allows users to generate cell lines suitable for clinical development without their own original cells, vectors, or previous experience in the field. ProBioGen significantly contributed to the performance of the Freedom ExpiCHO-S kit by leveraging its strong expertise in cell line and process development. The new series utilizes Thermo Fisher's ExpiCHO-S cell line, expanding the company's product portfolio for the CHO cell line development series.
|
Conclusion
In conclusion, the market shows promising growth prospects driven by expanding biopharmaceutical research and production. With the rising demand for biologics and vaccines, the need for efficient cell culture systems such as CHO cells is paramount. In addition, advancements in genetic engineering techniques enhance CHO cell productivity and versatility, further fueling market expansion. As the biopharmaceutical industry continues to evolve, the CHO cells market stands poised to capitalize on emerging opportunities, driving innovation and progress in drug development and production.
